Lucid Diagnostics Raises $15 Million in Series C Preferred Offering
PAVmed subsidiary Lucid Diagnostics raised $15 million in gross proceeds from accredited investors, selling 15,000 Series C Convertible Preferred shares at $1,000 each. The offering closed October 21, 2026.
Lucid Diagnostics, a subsidiary of PAVmed, secured 15 million in gross proceeds by selling 15000 shares of Series C Convertible Preferred Stock to accredited investors at 1000 per share. The offering closed on October 21, 2026. Lucid also agreed to file a registration statement covering…